OverviewChartNewsTraderScreen

BVT Knock-Out PFE/  DE000VD0NXQ0  /

Stuttgart
9/20/2024  9:45:25 PM Chg.-0.020 Bid10:00:40 PM Ask10:00:40 PM Underlying Strike price Expiration date Option type
0.590EUR -3.28% -
Bid Size: -		 -
Ask Size: -		 Pfizer Inc 22.85 USD 12/31/2078 Call
Newsfile Corp 9/20 INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mo...
TeleTrader 9/14 Pfizer reports positive data from experimental drug study
GlobeNewswire 9/3 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
TeleTrader 8/27 Pfizer launches digital platform to 'simplify' healthcare access
TeleTrader 8/22 FDA okays Moderna, Pfizer updated vaccines
GlobeNewswire 8/22 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire 8/16 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
TeleTrader 7/30 Pfizer's Q2 revenue rises by 2% to $13.3B
GlobeNewswire 7/17 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
TeleTrader 7/11 Pfizer advances once-daily version of weight loss pill
TeleTrader 7/9 Pfizer's chief scientific officer to leave after 15 years
GlobeNewswire 6/27 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire 6/5 Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire 6/3 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 5/16 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
TeleTrader 5/1 Pfizer's Q1 revenue drops 20% to $14.9 billion
GlobeNewswire 4/30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 3/22 Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire 3/20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 3/7 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire 3/7 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire 3/5 LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...
GlobeNewswire 2/28 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire 2/28 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire 2/27 Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment t...